Cargando…

Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy

Cancer/Testis Antigens (CTAs) are a promising class of tumor antigens that have a limited expression in somatic tissues (testis, ovary, fetal, and placental cells). Aberrant expression of CTAs in cancer cells may lead to abnormal chromosome segregation and aneuploidy. CTAs are regulated by epigeneti...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Carvalho, Fabricio, Vettore, André L., Colleoni, Gisele W. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310219/ https://www.ncbi.nlm.nih.gov/pubmed/22481966 http://dx.doi.org/10.1155/2012/257695

Ejemplares similares

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines
por: de Carvalho, Fabricio, et al.
Publicado: (2011)

An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients
por: Inaoka, Riguel J, et al.
Publicado: (2011)

Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4(+) and CD8(+) T-cell responses in multiple myeloma patients
por: Reinhard, H, et al.
Publicado: (2014)

Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma
por: Curioni-Fontecedro, A., et al.
Publicado: (2015)

Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases
por: Melo, Daniel Hardy, et al.
Publicado: (2017)

Erratum to “Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma”
por: Curioni-Fontecedro, A., et al.
Publicado: (2019)

Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma
por: Fernando, Rodrigo Carlini, et al.
Publicado: (2021)

Centrosomal Localisation of the Cancer/Testis (CT) Antigens NY-ESO-1 and MAGE-C1 Is Regulated by Proteasome Activity in Tumour Cells
por: Pagotto, Anna, et al.
Publicado: (2013)

Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2011)

MAGE cancer-testis antigens protect the mammalian germline under environmental stress
por: Fon Tacer, Klementina, et al.
Publicado: (2019)

MicroRNA-874 Functions as a Tumor Suppressor by Targeting Cancer/Testis Antigen HCA587/MAGE-C2
por: Song, Xiao, et al.
Publicado: (2016)

Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer
por: Mohsenzadegan, Monireh, et al.
Publicado: (2022)

Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2015)

Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

Publisher Correction: Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer
por: Mohsenzadegan, Monireh, et al.
Publicado: (2022)

P952: PROGNOSTIC SIGNIFICANCE OF DYNAMIC CHANGE OF MAGE-C1/CT7 IN MULTIPLE MYELOMA: TEN YEAR EXPERIENCE FROM A SINGLE CENTER
por: Dou, Xuelin, et al.
Publicado: (2023)

Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients
por: Freiberger, Sandra N., et al.
Publicado: (2022)

Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E
por: Hao, Jiaqing, et al.
Publicado: (2015)

The Use of MAGE C1 and Flow Cytometry to Determine the Malignant Cell Type in Multiple Myeloma
por: Wienand, Kirsty, et al.
Publicado: (2015)

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
por: Yousef, Sara, et al.
Publicado: (2015)

T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4
por: Coles, Charlotte H., et al.
Publicado: (2020)

Evaluation of MAGE-1 Cancer-Testis Antigen Expression in Invasive Breast Cancer and its Correlation with Prognostic Factors
por: Rastgoosalami, Mojtaba, et al.
Publicado: (2016)

Multiple myeloma cell lines and primary tumors proteoma: protein biosynthesis and immune system as potential therapeutic targets
por: Fernando, Rodrigo Carlini, et al.
Publicado: (2015)

MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4
por: Marcar, Lynnette, et al.
Publicado: (2015)

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers
por: Raghavendra, Ashwini, et al.
Publicado: (2018)

Expression and Prognostic Significance of Cancer/Testis Antigens, MAGE-E1, GAGE, and SOX-6, in Glioblastoma: An Immunohistochemistry Evaluation
por: Tabatabaei Yazdi, Seyed Abbas, et al.
Publicado: (2021)

MAGE-A Antigens and Cancer Immunotherapy
por: Zajac, Paul, et al.
Publicado: (2017)

The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma
por: Braga, Walter M. T., et al.
Publicado: (2012)

The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma
por: Zhang, Yao, et al.
Publicado: (2014)

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study
por: Matković, Božica, et al.
Publicado: (2011)

Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

PB1953: ASSESSMENT OF THE EFFICACY OF BORTEZOMIB-CONTAINING THERAPY REGIMENS DEPENDING ON MAGE-C1 GENE EXPRESSION IN MULTIPLE MYELOMA PATIENTS.
por: Eleonora, M., et al.
Publicado: (2022)

Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma
por: Hudolin, Tvrtko, et al.
Publicado: (2013)

Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma
por: Freitas, Marcelo Roberto Pereira, et al.
Publicado: (2013)

The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading
por: Vital, Domenic, et al.
Publicado: (2018)

Expanding the landscape of TCR gene therapy targeting MAGE
por: Mao, Zhiyuan, et al.
Publicado: (2023)

Evolutionary History of the Cancer Immunity Antigen MAGE Gene Family
por: Katsura, Yukako, et al.
Publicado: (2011)

MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer
por: von Boehmer, Lotta, et al.
Publicado: (2011)

MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
por: Mao, Yuan, et al.
Publicado: (2019)

The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?
por: Alsalloum, Alaa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_10of4d87s1nohd3tbbko41rt43